<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="504">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05154591</url>
  </required_header>
  <id_info>
    <org_study_id>SVF2015MeN-1</org_study_id>
    <nct_id>NCT05154591</nct_id>
  </id_info>
  <brief_title>CKDu Treated With Intra-arterial Infusion of Autologous SVF Cells</brief_title>
  <official_title>Chronic Kidney Disease of Unknown Cause (CKDu) Treated With Directed Local Intra-arterial Infusion of Autologous Stromal Vascular Fraction (SVF) Cells.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samuel Vilchez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministerio de Salud de Nicaragua</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GID BIO</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Autonomous University of Nicaragua</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Autonomous University of Nicaragua</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an interventional study to treat 18 patients with chronic kidney disease of unknown&#xD;
      cause (CKDu), formerly known as Mesoamerican nephropathy (MeN), with autologous adipose&#xD;
      tissue-derived stromal vascular fraction (SVF) cells transplanted by intra-arterial injection&#xD;
      both kidneys.&#xD;
&#xD;
      This study assesses: (1) safety and tolerability, (2) preliminary evidence of efficacy, (3)&#xD;
      exploratory evidence of clinical effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients under go 24 hours of preoperative hydration combined with N-actyl cysteine 300 mg IV&#xD;
      for prevention of nephrotoxicity. Under general anesthesia 200-300 cc of lipoaspirate is&#xD;
      collected into a sterile processing cannister (GID SFV-1, Louisville, CO, USA). The tissue is&#xD;
      washed and dissociated with collagenase (Worthington CLS-1, Lakewood, NJ, USA) at a&#xD;
      concentration of 200 CDU/ml of total volume for 50 minutes at 39°C. This is followed by&#xD;
      inactivation using 40 cc of human serum albumin. SVF cells are separated via centrifugation&#xD;
      for 10 minutes at 800 g. The cell pellet is extracted and resuspended in Harmann solution&#xD;
      with an aliquot (10 µl) removed for counting and viability assessment of resulting total&#xD;
      nucleated cells (YNC) through and image cytometer (ADAM MC, Portsmouth NH, USA).&#xD;
&#xD;
      Femoral artery catheterization is performed permitting advancement of a 100 cc balloon-tip&#xD;
      catheter into the renal artery under fluoroscopic control, with position confirmation using 1&#xD;
      cc of OrtoRay® 320 contrast diluted 1:4 with Hartmann solution. SVF cells are then admixed&#xD;
      with 200 cc Hartmann solution warmed to 37°C and in fused using a DRE infusion pump (DRE&#xD;
      Medical, Louisville, KY, USA) over a 15 minute period with constant agitation. On the 1st&#xD;
      pos-operative day creatinine and glomerular filtration rate are checked and the patient is&#xD;
      discharged.&#xD;
&#xD;
      Follow-up studies include clinical assessment, chemistries, and renal ultrasound to assess&#xD;
      intra-parenchymal renal volume, renal blood flow distribution, and hilar artery vascular&#xD;
      resistance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">February 28, 2021</completion_date>
  <primary_completion_date type="Actual">February 28, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open label for surgeons and radiologists&#xD;
Closed label for pathologists and nephrologists</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment related adverse events</measure>
    <time_frame>36-months follow-up post intervention.</time_frame>
    <description>Documentation of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Preliminary evidence of efficacy</measure>
    <time_frame>Assessment of changes between day 7 and month 36 post intervention.</time_frame>
    <description>Improvement in clinical parameter of GFR as compared with historical age and stage-matched controls.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal blood flow.</measure>
    <time_frame>Up to month 12 post intervention.</time_frame>
    <description>Distribution of intra-renal blood flow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney volume.</measure>
    <time_frame>Up to month 12 post intervention.</time_frame>
    <description>Changes in kidney size (cm3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal arterial resistive index.</measure>
    <time_frame>Up to month 12 post intervention.</time_frame>
    <description>Decreases in hilar artery resistance index (less o equal to 0.7).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Chronic Renal Failure of Unknown Cause</condition>
  <arm_group>
    <arm_group_label>Bilateral Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-arterial injection of SVF cells into the kidneys.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Adipose-derived stromal vascular fraction cells</intervention_name>
    <description>Kidney structural and functional changes in 18 patients after 36 months of treatment with SVF cells.</description>
    <arm_group_label>Bilateral Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Mesoamerican nephropathy&#xD;
&#xD;
          -  Stages 3 and 4&#xD;
&#xD;
          -  No other renal disease&#xD;
&#xD;
          -  No essential hypertension&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant abnormalities in laboratory tests that contraindicate surgical procedures.&#xD;
&#xD;
          -  Acute pathology or complications of significant chronic pathologies in the 6 months&#xD;
             prior to study entry, including, but not limited to:&#xD;
&#xD;
        Medical history of deep vein thrombosis Uncontrolled hypertension Active infection Reduced&#xD;
        cardiac ejection fraction Hepatitis B, C or HIV Diabetes treated with insulin or glucose&#xD;
        lowering agents Anemia (Hb &lt;9 g/dL) History of cancer Severe depression (Beck scale)&#xD;
        Autoimmune disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Carstens, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forrest Institute for Regenerative Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Diego Correa, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sreedhar Mandayam, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Escuela Oscar Danilo Rosales Arguello</name>
      <address>
        <city>Leon</city>
        <country>Nicaragua</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Nicaragua</country>
  </location_countries>
  <results_reference>
    <citation>Brown JC, Shang H, Li Y, Yang N, Patel N, Katz AJ. Isolation of Adipose-Derived Stromal Vascular Fraction Cells Using a Novel Point-of-Care Device: Cell Characterization and Review of the Literature. Tissue Eng Part C Methods. 2017 Mar;23(3):125-135. doi: 10.1089/ten.TEC.2016.0377. Review.</citation>
    <PMID>28177263</PMID>
  </results_reference>
  <results_reference>
    <citation>Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011 Jul 8;9(1):11-5. doi: 10.1016/j.stem.2011.06.008.</citation>
    <PMID>21726829</PMID>
  </results_reference>
  <results_reference>
    <citation>Carstens MH, Quintana FJ, Calderwood ST, Sevilla JP, Ríos AB, Rivera CM, Calero DW, Zelaya ML, Garcia N, Bertram KA, Rigdon J, Dos-Anjos S, Correa D. Treatment of chronic diabetic foot ulcers with adipose-derived stromal vascular fraction cell injections: Safety and evidence of efficacy at 1 year. Stem Cells Transl Med. 2021 Aug;10(8):1138-1147. doi: 10.1002/sctm.20-0497. Epub 2021 Apr 7.</citation>
    <PMID>33826245</PMID>
  </results_reference>
  <results_reference>
    <citation>Correa-Rotter R, García-Trabanino R. Mesoamerican Nephropathy. Semin Nephrol. 2019 May;39(3):263-271. doi: 10.1016/j.semnephrol.2019.02.004. Review.</citation>
    <PMID>31054625</PMID>
  </results_reference>
  <results_reference>
    <citation>Guo J, Nguyen A, Banyard DA, Fadavi D, Toranto JD, Wirth GA, Paydar KZ, Evans GR, Widgerow AD. Stromal vascular fraction: A regenerative reality? Part 2: Mechanisms of regenerative action. J Plast Reconstr Aesthet Surg. 2016 Feb;69(2):180-8. doi: 10.1016/j.bjps.2015.10.014. Epub 2015 Oct 24. Review.</citation>
    <PMID>26546112</PMID>
  </results_reference>
  <results_reference>
    <citation>Johnson RJ, Wesseling C, Newman LS. Chronic Kidney Disease of Unknown Cause in Agricultural Communities. N Engl J Med. 2019 May 9;380(19):1843-1852. doi: 10.1056/NEJMra1813869. Review.</citation>
    <PMID>31067373</PMID>
  </results_reference>
  <results_reference>
    <citation>Nguyen A, Guo J, Banyard DA, Fadavi D, Toranto JD, Wirth GA, Paydar KZ, Evans GR, Widgerow AD. Stromal vascular fraction: A regenerative reality? Part 1: Current concepts and review of the literature. J Plast Reconstr Aesthet Surg. 2016 Feb;69(2):170-9. doi: 10.1016/j.bjps.2015.10.015. Epub 2015 Oct 31. Review.</citation>
    <PMID>26565755</PMID>
  </results_reference>
  <results_reference>
    <citation>Wijkström J, González-Quiroz M, Hernandez M, Trujillo Z, Hultenby K, Ring A, Söderberg M, Aragón A, Elinder CG, Wernerson A. Renal Morphology, Clinical Findings, and Progression Rate in Mesoamerican Nephropathy. Am J Kidney Dis. 2017 May;69(5):626-636. doi: 10.1053/j.ajkd.2016.10.036. Epub 2017 Jan 23.</citation>
    <PMID>28126239</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 6, 2021</study_first_submitted>
  <study_first_submitted_qc>November 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2021</study_first_posted>
  <last_update_submitted>November 29, 2021</last_update_submitted>
  <last_update_submitted_qc>November 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>National Autonomous University of Nicaragua</investigator_affiliation>
    <investigator_full_name>Samuel Vilchez</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Stromal vascular fraction</keyword>
  <keyword>Mesenchynmal stem cells</keyword>
  <keyword>Chronic kidney disease</keyword>
  <keyword>Adipose stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

